{"title": "PDF", "author": "PDF", "url": "https://cancer.uci.edu/sites/default/files/2022-11/GU%20CA_1122%20.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Criteria Status Rezazadeh TBDS1823: A Prospective Observational Cohort to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell TumorsN/A Newly diagnosed germ cell or testicular non-germ cell tumor within 42 days of study registration. Open to accrual PI CRC Protocol #/Title Mechanism Primary In/Ex Criteria Status Hoyt TBDUCI 20-59: a Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer SurvivorsN/A Completion of chemotherapy for testis cancer within 2 years prior to consent. A score of < 1.8 on the goal navigation scale or < 0.6 on the goal facility scale of the CAYA or >4 on the Distress Thermometer. No lifetime history of psychiatric of cognitive disturbance as per self-report or medical record. No self-reported medical conditions that affect the immune system and would confound immune evaluation. Not a regular smoker (daily use).Pending activation PI CRC Protocol #/Title Mechanism Primary In/Ex Criteria Status Lee J. TranUCI 19-11: SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men with Newly Diagnosed Metastatic Prostate CancerCytoreductive Prostatectomy Histologically proven adenocarcinoma of the prostate. Evidence of metastasis by MRI/CT scan, bone scan, or histologic confirmation. Clinical stage M1a (distant lymph node positive), or M1b (bone metastasis). -If solitary lesion, metastasis confirmed with either biopsy or two independent imaging modalities (i.e. CT and PET, bone scan and MRI, modality at the discretion of the treating physician). No previous local therapy for prostate cancer. Started ADT no longer than 6 months prior to randomization. Patients who have chemotherapy, radiotherapy or oral antifungal agents (Ketoconazole, itraconazole, fluconazole) within 3 weeks prior to entering the study or those who have not recovered (e.g. back to baseline or grade 1) from adverse events due to agents administered more than 3 weeks earlier are excluded. Suspended Uchio N. De La RosaUCI-21-136: Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient PopulationPending activation PI CRC Protocol #/Title Mechanism Primary In/Ex Criteria 20-137: A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone- Sensitive Prostate Cancer randomization) metastatic hormone- sensitive prostate adenocarcinoma (small-cell tumors not eligible). PTEN deficiency Asymptomatic or mildly symptomatic Ongoing ADT with GnRH analogue or LHRH antagonist, or bilateral ochiectomy. Duration of ongoing ADT is 0 to a maximum of 3 months prior to randomization.Open to accrualTESTICULAR CANCER: Observational PROSTATE CANCER: Hormone-SensitiveTESTICULAR CANCER: Supportive Care PROSTATE CANCER: Surgical Candidates Page 1 of 14 November 2022Genitourinary PI CRC Protocol #/Title Mechanism Primary In/Ex Criteria Phase III Placebo-Controlled, Double-Blind in Combination with Abiraterone Acetate and Prednisone (AA-P) and ADT versus Abiraterone Acetate and Prednisone and ADT in Subjects with Metastatic Castration Sensitive disease documented by at least 1 bone lesion. Must have at least 1 deleterious germline started 14 days prior to randomization and willing to continue through the treatment phase. Participants who start a GnRH agonist 28 days prior to randomization will be required to take 1st gen anti-androgen for 14 days and discontinued prior to randomization. No small cell ductal or neurendocrine carcinoma of the prostate. No prior treatment with a PARP inhibitor, AR-targeted therapy, immunotherapy, or radiopharmaceutical agents with the exception of only 30 days of AA-P. No bisphosphonate or denosumab for bone metastasis 28 days before randomization. No history of adrenal dysfunction. No active malignancies other than the disease being treated under the study with the exceptions of: -Non-muscle invasive bladder cancer -Skin cancer treated 24 months and considered completely cured -Breast cancer - adequately treated lobular carcinoma in situ or ductal carcinoma in situ -Malignancy that is considered cured with minimal risk of recurrence No history of or current MDS/AML.Open to accrual Rezazadeh M. LeUCI 21-83: PSMAddition: An International Prospective Open-Label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination with Standard of Care, Versus Standard of Care Alone, in Adult Male Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)Lu-PSMA-617: PSMA- targeted radioligandInclusion: - Have at least one bone met, soft tissue, visceral lesion w/in 28 days prior to randomization -minimally treated with up to 45 days of LHRH, dicon prior to study therapy or 45 days after start of LHRH. Up to 45 days of CYP17 inhibitor or ARDT exposure. No CYP17 inhibitor or ARDT exposure for earlier stages of pristate cancer. Exclusion: - Require urgent exposure to taxane-based chemo - prior systemic anti-prostate cancer therapy, chemotherapy, Polypolymerase (PARP) inhibitors, immunotherapy or biological therapy - Previous treatment months of randomization: Strontium-89, radioligand therapy - Symptomatic cord compression - Any condition that precludes raised arms positionOpen to accrual Uchio Inhibition with dArolutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Men with Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm (ARASEC)Androgen Receptor InhibitionOpen to accrualPROSTATE CANCER: Hormone-Sensitive Page 2 of November 2022Genitourinary PI Mechanism Primary In/Ex TBD UCI 22-52: A Phase II Open-Label Extension Study for Subjects with Prostate Cancer who Previously Participated in an Enzalutamide Clinical StudyPending activation Seyedin M. LeNRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk And Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (Predict-Rt*) Pathologically confirmed adenocarcinoma of prostate within 180 days prior to registration. High-risk disease defined as having at least one of the following: PSA > 20 ng/mL prior to starting ADT, cT3a-T4 by digital exam, gleason score of 8-10, or node positive by conventional imaging with a short axis of at least 1.0 cm. No metastatic disease outside of the pelvic nodes. No prior systemic chemotherapy within 3 years prior to registration for the cancer on study. No prior prostatectomy. No prior radiotherapy to the re3gion of the study cancer that would result in overlap of radiation therapy fields.Open to accrual PI CRC Protocol #/Title Mechanism Primary In/Ex Criteria Status Mar M. PopalUCI 16-76: Phase Ib/II Trial of Pembrolizumab PD-1/PD-L1/PD- L2 Confirmed prostate adenocarcinoma without small cell histology. Progression within 6 months prior to screening. Ongoing androgen deprivation. No prior radium/radiopharmaceutical treatment.Pembro Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate A Phase I/II, Open-Label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients with Metastatic Castration Resistant Prostate CancerARV-110: AR protein degraderPart B - Phase 2 Cohort Expansion Testosterone <50 ng/dL 1-2 prior second generation anti-androgen agents for CRPC. Subgroup 1: Tumors harboring AR T878 and/or H875 mutations. -At most 1 chemotherapy regimen in CSPC and CRPC settings. Subgroup 4: Less pre-treated group. -Received only 1 prior AR second generation therapy either as treatment for CSPC or CRPC and no more than 1 regimen in CRPC setting. -No prior chemotherapy.Suspended Rezazadeh A. MacaraegUCI 21-07: A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic prostate without pure neuroendocrine differenciation or small cell. No prior abiraterone or treatment with a taxane. Must have bilateral orchiectomy or on continueous ADT with a gonadotropin releasing 2022Genitourinary PI CRC Randomized, Active-Controlled, Phase of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients who have Failed Prior Treatment with at Least One Androgen Receptor Targeting Agent (VERACITY)VERU-111: microtubule fragmentationOpen to accrual Mar M. LeETCTN-10301: A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab by bone scan. 1 LN metastases allowed (LN must measure <3 cm in the longest dimension). Visible visceral organ metastases are not allowed. Progression after abiraterone, enzalutamide, docetaxel, or other secondary hormonal therapy. There is no maximum number of prior therapies. No prior therapy with radionuclides, hemibody external radiation, or systemic radiotherapy with radioisotopes. Able to discontinue medications that are potent inhibitors, inducers or sensitive substrates of CYP3A4/5 or CYP2C19. Able to discontinue concomitant H2 blockers or PPIs.Open to accrual PI CRC Protocol #/Title Mechanism Primary In/Ex Criteria Status Ahlering B. Morales UCI 98-41 Outcomes and Assessment of Prostate Cancer at UCIMC Radical Prostatectomy Open to accrual *IRB Expried AhleringE. Huang; Prostatectomy Outcome AssessmentOnline questionnaireOpen to accrual Uchio TBDUCI-17-40: Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment ResponseQuestionnaire *Adult males aged 18 years to 79 years old * Diagnosis of prostate cancer, clinical stage T1 or T2, with no evidence of metastasis * PSA less than 50 ng/mL *Not previously undergone any treatment for prostate cancer *Diagnosis of prostate cancer less than 6 months before baseline visitOpen to accrual BristowD. Garcia; A. VargasUCI 19-25: Baseline Assessment of Cancer Health Disparities in Underserved Populations in CaliforniaN/A Adults diagnosed with prostate cancer 18 and over. Pending activation Uchio TBD UCI 19-48: Study of Prostate Ablation Related Energy Devices (SPARED) Registry Pending activation Ahlering E. HuangUCI 00-55: Retrospective Evaluation of Prostate Cancer Clinical and Pathological to accrual Dayyani TBDUCI 22-109: A Randomized, Double-blind, Double-dummy, Parallel Group Study Assess the Efficacy and Safety of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic ChemotherapyPending activationPROSTATE CANCER: Non-TreatmentPROSTATE CRC Protocol #/Title Mechanism Primary B. 20-123: An Open-Label, Randomized, III Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-Line or Third- Line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After clear cell component with or without sarcomatid features. Has experienced disease progression on or after first or second line systemic therapy with an anti- PD-1/L1 therapy for locally advanced/metastatic RCC, but no more than one anti-PD-1/L1 therapy. No more than 2 prior systemic regimens for locally advanced/metastatic RCC. Open to accrual Freuhauf B. RobertsonUCI 20-124: An Open-Label, Randomized Phase III Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First Line Treatment in Participants with Advanced Clear Cell Renal Cell with clear cell component with or without sarcomatoid features. No prior systemic treatment for ccRCC. No other active malignancy.Open to accrual Rezazadeh K. PrajapatiUCI 21-228: A Multi-Center, Double-Blind, Randomized Phase III Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Controlled, Multicenter, Open-Label Study Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint InhibitorPending activation PI CRC Protocol #/Title Mechanism Primary Renal BiopsyProspective No coagulopathy or other bleeding disorder. No active urinary tract infections. No requirement to take, Aspirin or Coumadin.Open to accrualRENAL CANCER: Non-TreatmentRENAL CANCER: Adjuvant Page 5 of November 2022Genitourinary PI CRC Protocol #/Title Mechanism Primary R. YoonUCI-15-22: Electro-Phage and Colorimetric Aptamer Sensors for Clinical Staging and Monitoring of Bladder CancerOpen to accrual Uchio P. DuffyUCI 18-53: A Phase III, Randomized, Comparator-Controlled Clinical Trial to Study the Efficacy of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with Intermediate or High Invasive Bladder Cancer (KEYNOTE-676)Anti PD-1/PD-L1/PD- L2 BCG refractory. Failed one prior course of BCG. Confirmed diagnosis of high risk non-muscle-invasive (T1, High Grade Ta and/or CIS) bladder TCC. No muscle invasive (T2-T4), locally advanced non-resectable, or metastatic urothelial carcinoma. 9 Doses of BCG within the last 9 months.Open to accrual Uchio TBDUCI 20-210: A Phase III of CG0070 in Patients with Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)CG0070: engineered oncolytic adenovirus Pathologically confirmed BCG unresponsive CIS. Have all Ta and/T1 disease resected and all CIS resected or fulgurated. Ineligible for radical cystectomy or Uchio TBDUCI 21-37: (ENLIGHTED) TRIAL: Multicenter Phase and Efficacy of TOOKAD (Padeliporfin) Vascular Targeted Photodynamic Therapy Treatment vascular disruptor New or low-grade, non-invasive UTUC disease. Up to 2 biopsy-proven sites of low-grade involvement with the largest rumor between 5 mm and 15 mm in diameter, located in the calyces, renal pelvis, or in the ureter of ipsilateral kidney, with an absense of high-grade cells on cytology. No current high-grade, or muscle invasive urothelial carcinoma of the bladder. No current or previous CIS in the upper urinary tract. No history of invasive T2 urothelial cancer in the past 2 years. No BCG or local chemotherapy in the upper urinary tract within 2 months of enrollment. No systemic chemotherapy within 2 months of enrollment.Pending activation Uchio TBDUCI 21-41: A Study of Intravesical Enfortumab for of Patients with Non-Muscle Invasive CancerPending activation Uchio P. DuffyUCI 22-69: A Phase I/II Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC Patients Who Are BCG Na\u00efve Received Incomplete BCG TreatmentPending activation PI CRC Protocol #/Title Mechanism Primary In/Ex Criteria Status Rezazadeh UCI 21-09: A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder the bladder with clinical stage of T2- 4aN1M0 (transitional and mixed transitional/non-transitional/variant cell histologies are accepted). Medically fit for cystectomy and able to receive neoadjuvant therapy.Open to accrual Uchio TBDUCI 21-69: A Phase III, Multi-Center, Randomized Study Evaluating Efficacy of TAR-200 in Combination with Cetrelimab Versus Concurrent Chemoradiotherapy in Participants with Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who within 90 days of randomization. Squamous cell and transitional cell subtypes allowed. Ineligible for or elected to not undergo radical cystectomy. No other active malignancies. No urothelial carcinoma or histological variant at any site outside of the urinary bladder. Ta/T1/CIS of the upper urinary tract (including renal pelvis and ureter) is allowed if treated with complete nephrourectomy within 24 months. No intervening intravesical chemotherapy or immunotherapy from the time of most recent TURBT to starting study treatment. No Prior therapy with anti-PD-1, anti-PD-L2, or with an agent directed to Invasive November 2022Genitourinary PI CRC Protocol #/Title Mechanism Primary In/Ex II, TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for Criteria Status Yaacoub B. RobertsonSWOG S1806: Phase III Trial of Concurrent Chemoradiation with or without Atezolizumab for Localized Muscle Invasive Bladder CancerAnti PD-1/PD-L1 Histologically proven T2-T4a N0 M0 UC of the bladder within 70 days of randomization (small cell carcinoma excluded). Patients must undergo a TURBT within 70 days prior to randomization. ECOG 0-2. No diffuse CIS based on cystoscopy and biopsy. No prior pelvic radiation. No prior treatment for MIBC including neoadjuvant chemotherapy for current tumor.Open to accrual - only at Orange Rezazadeh TBDUCI 22-128: A Phase I/II Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD- 1/L1 Phase II Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety Disitamab Vedotin (RC48-ADC) UC originating from the renal pelvis, ureters, bladder, or urethra. Mixed-cell type tumors are eligible as long as urothelial cell carcinoma is the predominant cell type * Subject must have received 1 or 2 lines of prior systemic therapy for LA/mUC, including 1 line of platinum-containing chemotherapy * HER2-expressing status determined by the central laboratory to be IHC 1+, 2+ or 3+ Ex: * Known hypersensitivity to disitamab vedotin or any of its components * Toxicity from a previous treatment has not returned to Grade 0-1 * Prior CANCER: Invastive Page 7 of 14 November 2022Genitourinary PI CRC Protocol #/Title Mechanism Primary In/Ex Criteria Status Mar M. LeETCTN-10100: A Randomized, Phase II Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based cancer the reval pelvis, ureter, urinary bladder, or urethra. PD-L1 status determined centrally by HistogeneX. May have up to two prior lines of chemotherapy for advanced disease. No prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents or eribulin.Open to accrual Rezazadeh M. PopalETCTN-10144: A Phase II Study of Olaparib (AZD2281) of the urothelial tract/bladder cancer. Disease progression during treatment or after the most recent dose of therapy with at least one platinum-based regimen and/or an immune-checkpoint inhibitor. No prior treatment with or any other PARP inhibitor. No myelodysplastic syndrome/acute myeloid leukemia. Cohort 1: Have confirmed presence of high TMB or one or more of the following genes: BRCA1, BRCA2, ATM, BAP1, MSH2, PALB2, and BRIP1 Cohort 2: Have confirmed presence of one or more of the DNA-repair genes tested in the FoundationOne FoundationOne\u00ae CDx (F1CDx) panel excluding the ones in cohort 1. Cohort 3: Patients without eligible cancer-associated DNA-repair gene mutations will be followed for outcomes and blood collection.Open to accrual PI CRC Protocol #/Title Mechanism Primary In/Ex Criteria Status Ahlering L. UCI Using Virtual Reality (VR) Models for Preoperative Planning VR models Have a prostate, kidney, or liver mass with at least one course of treatment that may be an operation in which the CT scan or MRI would be viewed during surgical planning and during the operation.Open to accrual Nagasaka K. ButtigiegUCI 19-57: A Phase Safety, Tolerability, Activity of TPX-0022, A Novel Met/CSF1R/SRC Inhibitor, in Patients with Advanced Solid Tumors Harboring Genetic Alterations In MetTPX-0022: MET/CSF1R/SRC inhibitor Dose escalation: Histological/cytological confirmation of advanced/metastatic solid tumors harboring the genetic MET alteration(s) including exon 14 deletion (METex14), amplification, fusion or activating kinase mutation, who are resistant or intolerant.Open to accrual Ou K. ButtigiegUCI 19-64: A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid TumorsHER2, HER3, NRG1 Must have received prior standard therapy appropriate for their tumor type and stage of disease, or in the opinion of the Investigator, would be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy. Locally-advanced unresectable or metastatic solid tumor malignancy with documented NRG1 gene fusion, identified through molecular assays such as PCR, next generation sequencing-based assays [DNA or RNA], or FISH as routinely or other similarly-certified laboratories.Open to accrualBASKET TRIALSUROTHELIAL CANCER: Locally Advanced or Metastatic 8 of 14 November 2022Genitourinary PI CRC Protocol #/Title Mechanism Primary In/Ex Phase I/II, First-In-Human, Multi-Part, Open-Label, Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients with Locally Advanced or Metastatic Solid TUmors, and Expansion in Selected cells; advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary urothelial, urethra). Primary tumor must have documented HER2 expression by immunohistochemistry. ECOG status of 0 or 1 at study entry and life expectancy of at least 3 months. Have recieved 1 platinum-containing regimen for inoperable locally advanced or metastatic urothelial carcinoma with radiographic progression or recurrent disease. Must have received treatment with a checkpoint inhibitor with radiographic progression.Open to accrual Nagasaka C. GonzalezUCI 20-68: A Phase II Study of Seribantumab (FTN100) in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid TumorsSeribantumab: ERBB inhibitor Locally advanced or metastatic solid tumor with an NRG1 gene fusion Needs 1 prior standard therapy in the locally advanced or metastatic setting ECOG 0-2 Cohort 1 only: no previous ERBB/HER2/HER3 Rezazadeh M. PopalUCI First-in-Human SHP2 Inhibitor BBP-398 (Formerly Known IACS-15509) in Patients with Solid TumorsBBP-398: SHP2 inhibitorDose Expansion Phase: Advanced or other MAPK-pathway alterations (excl. BRAF V600X) with no available standard of care or curative therapies. Cohort A: Advanced or metastatic KRAS G12C of NSCLC with no available standard of care or curative therapies. Cohort B: Advanced or metastatic KRAS G12C of non-NSCLC with no available standard of care or curative therapies. Cohort A: Advanced or metastatic NF1 LOF solid tumor with no available standard of care or curative therapies. Cohort D: Advanced of metastatic EGFR-mutant NSCLC that progressed on standard of care EGFR TKI therapies, with no available standard of care or curative therapies.Open to accrual Ou C. RamirezUCI-20-194: A Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subject with Advanced or Metastatic Solid Tumors with KRasG12C MutationD-1553: novel, targeted KRAS inhibitor Inclusion: - Subject has KRASG12C mutation in tumor tissue or blood, pleural effusion or other samples containing cancer cells or DNA - Subject has adequate hematologic function, renal function, liver function, and coagulation function Exclusion: - Prior KRASG12C targeted therapy - Significant cardiovascular disease, lung disease, GI disease (or function) - currently receiving or planning to receive medications known to be substrate of CYP3A4Open to accrual Dayyani J. BalangueUCI 20-213: Phase I Antibody (mAb) JTX-8064, as Monotherapy and in with a Programmed Cell Death Receptor-1 (PD- 1) Inhibitor, in Adult Subjects with and 2: Histologically or cytologically confirmed advanced/metastatic extracranial solid tumor. - Cohort 4A: 2L/3L clear cell renal cell carcinoma . Subjects just have progressed on or after prior PD-(L)1 therapy.Open to accrualBASKET TRIALS Page 9 of 14 November 2022Genitourinary PI CRC Protocol #/Title Mechanism Primary In/Ex Criteria Status Dayyani J. BalangueUCI 21-10: A Phase I Dose-Escalation and Dose Expansion Study of TJ033721 in Subjects with Advanced or Metastatic Solid TumorsTJ033721: anti CLDN18.2 and anti 4- 1BB Histologically confirmed advanced or metastatic solid tumor whose disease has progressed despite standard therapy who have no available standard treatment options. No prior exposure to CLDN18.2 - targeted therapy or 4-1BBagonists.Open to accrual Dayyani B. 21-11: A Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regiments, in Patients with Advanced Solid TumorsTT-00420: Aurora A/B and Janus kinase inhibitor Histopathological or cytologically confirmed locally advanced or metastatic solid tumors who have no available standard therapeutric treatment options. No hematologic malignancy, including leukemia (any form), lymphoma, and multiple myeloma. No history of primary central nervous system tumors or carcinomatous meningitis.Open to accrual Ou R. ChangUCI inhibitorDose-Escalation Phase: Participants with relapsed or refractory solid tumors who have failed, or are intolerant to, or are considered ineligible for standard-of-care therapies. Dose-Expansion Phase: Participants with relapsed or refractory solid tumors harboring certain specific mutations/rearrangements that result in hyperactivation of accrual (Cohort 4c closed) Nagasaka R. ChangUCI-21-13: Phase I/II Study of BT5528 in Patients with Advanced Malignancies Associated with EphA2 ExpressionBT5528: bicycle toxin conjugate targeting EphA2Part A Histologically confirmed metastatic recurrent melignany solid tumor who must have exhausted all appropriate treatment options per local guidelines and must have failed at least one prior line of therapy with evidence of radiographic progression on the most recent line. Cohort A1-4 for Part A-1 monotherapy or Cohort A2-3 for Part A-2 combination therapy must have tumor tissue with confirmation of positive EphA2 tumor expression. Patients with ovarian or urothelial cancer in Cohort 1-4 for Part A-1 monotherapy or Cohort A2-3 for Part A-2 conbination therapy must have tumor tissue available but may be enrolled without prior confirmation of EphA2 tumor expression. Part B Histologically confirmed metastatic recurrent disease that is non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, gastric/upper gastrointestinalcancer, head and neck cancer, or urothelial cancer. Must have failed or are ineligible for all appropriate treatment options per local guidelines and have evidenace of radiographic progression on the most recent line of therapy.Open to accrual Moyers N. FerrandUCI 21-38: An Open Label, First in Human (FIH), Phase I Trial of LVGN6051 as Single Agent and in Combination with or unresectable malignancy, forewhich they have received all standard therapy or have been unable to tolerate standard therapy.Open to accrual Valerin B. HuynhUCI 21-40: A Phase I/II, First-in-Human, Multi-Part, Open-Label, Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected IndicationsDF6002: monovalent IL12-Fc; Nivolumab: Anti-PD- 1 1b: Histologically or cytologically proven locally advanced or metastatic solid tumors, forwhich no standard therapy exists or standard therapy has failed among the following tumor types: meanoma, NSCLC, small cell lung, head and neck squamous cell, urothelial, gastric, esophageal, cervical, hepatocellular, Merkel cell, cutaneous squamous cell carcinoma, renal cell, endometrial, TNBC, ovarian, and prostate.Open to accrual Ou K. ButtigiegUCI 21-47: A Phase I/II Study of the Highly Selective ROS1 Inhibitor NUV-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1) Histologically or cytologically confirmed metastatic solid tumors with documented ROS1 rearrangement. No primary driver alteration other than ROS1. For example, NSCLC with a targetable mutation in EGFR, ALK, MET, RET, or BRAF.Open to accrualBASKET TRIALS Page 10 of 14 November 2022Genitourinary PI CRC Protocol #/Title Mechanism Primary In/Ex Criteria Status J. ChoeUCI 21-53: A Phase Ia/Ib Study of TumorsLY3537982: KRAS- G12C inhibitor* Must have KRASG12C mutation in tumor tissue or circulating tumor DNA * Proven diagnosis of locally advanced, unresectable, and/or metastatic cancer * No active fungal, bacterial, or viral disease * No resrious cardiac conditions * No prior treatment with any KRAS G12C small molecule inhibitor, except in P1A dose esc. cohort and cohort E1. Open to accrual Nagasaka J. ChoeUCI 21-62: Phase I/II Study Investigating Activity in Combination with Anti-PD-1 Advanced Solid TumorsBGC-A425: anti-TIM- 3: Tislelizumab: anti- PD-1Inclusion: - Patient has not received prior therapy targeting TIM-3 - must meet the Child-Pugh A classification for liver function w/in 7 days before first dose - ECOG 1 Exclusion - Active untreated brain mets - history of interstitial lung disease - undergone any major surgical procedure within 28 days before 1st treatment - hypersensitivity to monoclonal antibodies - received any herbal medicine or Chinese patent medicines used to control cancer within 14 days of 1st dose - Was administered a live vaccine 28 days prior to study - Underlying medical conditions or alcohol or drug abuse or dependenceOpen to accrual Fortier TBDUCI 21-127: Goal Directed Intervention for Adolescent and Young Adult Cancer SurvivorsInterview Age 15-21 at the time of consent. Completion of primary medical treatment for cancer within 1 year at the time of consent.Pending activation Dayyani TBDUCI 21-146: An Open-Label, Multi-Center, Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in Patients with Tissue Factor Positive Advanced or Metastatic Solid TumorsMRG004A: antibody- drug conjugate Part B Documented Tissue Factor in tumor biopsy by immunohistorychemisty. Histologically or cytologically confirmed unresectable or metastatic cancer with disease progression during prior therapy, or relapse or progression following approved standard therapy for their tumor types.Open to accrual Nagasaka A. AguilarUCI 21-161: A Phase I/II Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid TumorsBA3021: antibody PD-1 checkpoint inhibitorPending activation Zell TBDUCI 21-174: Preserving Medical Records after a Cancer Diagnosis for Subsequent Generations to UsePending activation Moyers TBDUCI 21-175: A Study Evaluating the Clinical Activity and Safety of Approved Drugs Within Biomarker-Guided Patients with Solid TumorsPending activationBASKET TRIALS Page 11 of 14 November 2022Genitourinary PI CRC Protocol #/Title Mechanism Primary K. GomezUCI 21-189: A Multicenter, Open-label, Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer in Participants with Selected Solid TumorsMK-7684: anti- TIGIT; MK-3475: anti PL-1 squamous cell carcinoma, adeonosquamous carcinoma, or adeonocarcinoma of the cervix which has progressed on satandard of care chemotherapy. Cohort B: Histologically or cytologically confirmed advanced endometrial cancer that has progressed after 1 prior systemic platinum-based chemotherapy. May have had up to 2 lines of platinum-based chemotherapy if 1 was in the neoadjuvant or adjuvant treatment setting. Cohort C: Histologically or cytologically confirmed advanced HNSCC that is considered incurable by local therapies and whose tumor express PD-L1 (CPS1). Cohort D: Histologically or cytologically confirmed advanced unresectable biliary adenocarcinoma that has progressed after 1 prior systemic therapy. No mixed HCC/cholangiocarcinoma or Ampulla of Vater cancers. Cohort E: Histologically or cytologically confirmed advanced adeonocarcinoma squamous cell of the esophagus or advanced/metastatic Siewert type I adenocarcinoma of the GEJ that is unresectable and not previously treated with systemic therapy. Cohort F: Histologically or cytologically confirmed local TNBC that is locally unresectable but not previously treated with chemotherapy and cannot be treated with curative intent or metastatic that has not been previously treated with chemotherapy. Cohort G: Histologically, radiologically, or cytologically confirmed HCC excluding fibrolamellar, sarcomatoid, or mixed cholangio-HCC tumors that has not been previously treated with systemic therapy.Open to accrual Chow M. NguyenUCI 21-208: An Open-Label, Multicenter, Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects with Relapsed and/or Refractory Solid CancersIGM-8444: agonistic IgM antibodyIn: * Patients who are either refractory to or intolerant of existing standard therapy or for whom no effective further standard of care therapy exists * No more than three prior therapeutic regimens Ex: * Prior DR5 agonist therapy * Prior Bcl-family inhibitor therapy * Concomitant use of agents well known to cause liver toxicity * Current treatment with medications that are well known to prolong the QT interval * History of severe allergic or anaphylactic reactions to antibody therapy * Palliative radiation to bone metastases within 2 weeks prior to Day 1 * Major surgical procedure within 4 weeks prior to Day 1Open to accrual Chow TBDUCI 21-229: Phase I, Open-Label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella Typhimurium SGN1 in Patients with Advanced Solid TumorSGN1: Open-Label, Phase I Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Malignancies Including LymphomaTAB004: An Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, Pharmacokinetics, and Preliminary Activity of BTX-1188 in Subjects with Advanced MalignanciesBTX-1188: GSPT1 Open-Label, Multicenter, Phase I Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 with Dose Expansion Phase, in Subjects with Advanced Solid TumorsAndrogen and glucocorticoid receptor antagonist Part 1 (Dose Escalation): histologically or cytologically confirmed relapsed or refractory advanced or metastatic solid tumor of any origin, not amenable to standard of care therapy Measurable or evaluable disease per RECIST v1.1 criteria Exclusion: Known brain metastases, spinal cord compression, carcinomatous meningitis or leptomeningeal disease unless appropriately treated and neurologically stable for > 4 weeksOpen to accrualBASKET TRIALS Page 12 of 14 November 2022Genitourinary Tewari K. GomezUCI 22-78: A Phase I Study of KSQ-4279 Alone and in Combination in Patients with Advanced Solid TumorsPending activation Ou K. ButtigiegUCI 22-87: Phase I/IB Multicenter Open-Label Study of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Specific Mutations in KRASPending activation Ou TBDUCI 22-88: Phase I/IB, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid TumorsPending activation Page 13 of 14 November 2022Genitourinary PI CRC Protocol #/Title Mechanism Primary TBDUCI 22-107: A Phase IB, Dose-Escalation Study of the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Patients with Relapsed or Refractory activation SWOG S1609 DART: Dual Anti-CTLA-4 Rare Tumors Bota D. Na ECOG EAY131: Molecular Analysis for Therapy Choice (MATCH) Varies per mutation Positive for specific mutations. Open to accrual Kong M. TharaniETCTN-10129: A Phase II Study of the PARP Inhibitor Olaparib in IDH1 and IDH2 Mutant Advanced Solid TumorsPARP Inhibitor Diagnosed with solid malignant tumor that has progressed despite standard therapy, or for which no effective standard therapy exists. Biopsy confirmation of an IDH1 or IDH2 mutation associated with neomorphic activity of the encoded proteins. No prior treatment with any PARP inhibitor, including olaparib. No other melignancy within the last 5 years except: treated non-melanoma skin cancer, treated in situ cancer or the vervix, ductal carinoma in situ, stage 1, grade 1 endometrial carcinoma, or other solid tumors including lymphomas (without bone marrow involvement).Open cancer identified in \u00a718.1, NOS rare tumors, or tumor of unknown primary cohorts. PD following 1 line of standard therapy and there must not be other approved/standard therapy available that has been shown to prolong OS. Includes patients who cannot receive standard therapy due to medical issues. 4 Week washout of prior anti-CTLA-4 or anti-PD-1/anti-PD-L1 therapy prior to registration.Open to accrualBASKET TRIALS "}